This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
IntroductionSystemic inflammation is recognised as a critical driver of atherosclerotic cardiovascular disease (ASCVD), especially in patients with comorbid chronic kidneydisease (CKD).
A session at the 18 th Annual Cardiometabolic Health Congress (CMHC), explored the intersection of cardiometabolic conditions such as obesity and insulin resistance with liver disease, beginning with some important new updates on the preferred terms for these diseases. Available at: [link] (Accessed: October 24, 2023).
METHODS:The AHA, through its Epidemiology and Prevention Statistics Committee, continuously monitors and evaluates sources of data on heart disease and stroke in the United States and globally to provide the most current information available in the annual Statistical Update with review of published literature through the year before writing.
BackgroundIn 2023, the American Heart Association defined the concept of cardiovascularkidneymetabolic (CKM) syndrome as a health disorder ascribed to connections among obesity, diabetes, chronic kidneydisease, and cardiovascular disease. Journal of the American Heart Association, Ahead of Print.
2023, the American Heart Association (AHA) issued a presidential advisory on the urgency of this systemic disorder involving heart disease, kidneydisease, diabetes and obesity. The virtual, self-paced Foundations of Cardiometabolic Health Certificate Course is the first step to attaining the CCHP credential.
For instance, a pediatric provider may be only interested in topics pertaining to childhood obesity. They could find resources and education focused on that condition within both the Obesity Management and Pediatrics hubs. ” Learners can see some of the CMHC experts in person on Aug.
Getty Images milla1cf Fri, 12/08/2023 - 08:17 December 8, 2023 — The American College of Cardiology (ACC) and the American Heart Association (AHA), along with several other leading medical associations, have issued a new guideline for preventing and optimally managing atrial fibrillation (AFib).
2 Most are balancing multiple comorbidities, such as obesity, diabetes, hypertension and chronic kidneydisease (CKD). 2023; Oct;29(10):1412-1451. Epub 2023 Sep 26. A Trial to Learn How Well Finerenone Works and How Safe it is in Adult Participants With Non-diabetic Chronic KidneyDisease (FIND-CKD).
Can you please explain the concept of an obesity paradox? Salvatore Carbone, PhD: First, I’d like to point out that obesity is a major risk factor for cardiometabolic disease. 2, 3] This association is more pronounced for those with class I obesity, which is a body mass index (BMI) between 30-35 kg/m2.
11 Despite the link between inflammation and cardiovascular disease has been proven by extensive research, most physicians have focused on treating high-risk patients with lipid lowering therapies including statin therapy.1,12,13 As of June 2023, the U.S. Accessed November 8, 2023. Accessed January 18, 2023. μ/L on 0.6
Published on November 30, 2023, in the Journal of the American College of Cardiology, these new guidelines are based on a comprehensive literature review from May 2022 to November 2022, and provide important recommendations to clinicians caring for patients with or at risk of developing cardiovascular disease (CVD). J Am Coll Cardiol.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content